Neoplasms, Germ Cell and Embryonal

148 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Broader: Neoplasms

Narrower: Astrocytoma 52, Carcinoid Tumor 2, Carcinoma, Medullary 1, Carcinoma, Neuroendocrine 3, Chordoma 3, Craniopharyngioma 2, Ganglioneuroblastoma 2, Glioblastoma 44, Glioma 116, Gliosarcoma 8, Medulloblastoma 8, Neuroblastoma 5, Neuroectodermal Tumors, Primitive 15, Neuroendocrine Tumors 17, Oligodendroglioma 2, Pheochromocytoma 2, Seminoma 2

Treatments and conditions

Neoplasms, Germ Cell and Embryonal
Treatment and conditionWhere it standsTrials
[11C]AZ1419 3391 + Palacaparib for astrocytomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
[11C]AZ1419 3391 + Palacaparib + Temozolomide for astrocytomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
61Cu-NODAGA-LM3 + Comparator for neuroendocrine tumorsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
68-Gallium DOTATATE for neuroectodermal tumors, primitivePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
68-Gallium DOTATATE for neuroendocrine tumorsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Accelerated Hypofractionated Radiation Therapy for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Aldara - Imiquimod 5% + IDH1R132H-vac for astrocytomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Aldara - Imiquimod 5% + IDH1R132H-vac + Vorasidenib hemicitric acid hemihydrate for astrocytomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Allogeneic genetically modified gamma-delta T cells for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Anti-PD-1 monoclonal antibody + LCB84 for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Atezolizumab for carcinoma, neuroendocrinePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration for glioblastomaTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration for gliosarcomaTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration for oligodendrogliomaTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration + NIVOLUMAB for glioblastomaTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration + NIVOLUMAB for gliosarcomaTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration + NIVOLUMAB for oligodendrogliomaTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Autologous genetically modified gamma-delta T cells for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Autologous hALK.CAR T cells for neuroblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
autologous NK cell plus GD2 antibody for neuroblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Avelumab for gliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy + Biospecimen Collection + EFINEPTAKIN ALFA + PEMBROLIZUMAB for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy + Biospecimen Collection + EFINEPTAKIN ALFA + PEMBROLIZUMAB for gliosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Multigated Acquisition Scan + Radiologic Examination + OSIMERTINIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Radiologic Examination + Crizotinib for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Laboratory Biomarker Analysis + Radiologic Examination + PERTUZUMAB + TRASTUZUMAB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Blood Sample + Cerebrospinal Fluid (CSF) Sample + Chemotherapy Drug, Cancer - Physician's Choice + Non-Investigational Surgical Resection + Radiotherapy (RT) + Tumor Tissue Sample + Temozolomide for neuroectodermal tumors, primitivePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Brain surgery + RETIFANLIMAB + RAGIFILIMAB for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Brain surgery + SRS + RETIFANLIMAB + RAGIFILIMAB for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cabozantinib for carcinoid tumorPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cabozantinib + NIVOLUMAB for carcinoid tumorPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + ELRAGLUSIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + ELRAGLUSIB + Paclitaxel for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Chemotherapy + MAPK inhibitors + ARSENIC TRIOXIDE for neuroblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CTX-471 + Tovecimig for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ADAVOSERTIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + AFATINIB + AFATINIB DIMALEATE for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Binimetinib for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + CAPIVASERTIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + COPANLISIB HYDROCHLORIDE + COPANLISIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Crizotinib for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Dasatinib for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + DEFACTINIB + DEFACTINIB HYDROCHLORIDE for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Fexagratinib for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + GSK-2636771 for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + IPATASERTIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB + RELATLIMAB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Palbociclib for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + SAPANISERTIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TASELISIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib + Dabrafenib Mesylate + DABRAFENIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TRASTUZUMAB + TRASTUZUMAB EMTANSINE for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ULIXERTINIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dabrafenib, trametinib, nivolumab for gliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dose-escalated radiation therapy for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dose-intensified Accelerated Photon Beam Radiation Therapy for glioblastomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dose-intensified Photon Beam Radiation Therapy for glioblastomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Doxorubicin hydrochloride + ELRAGLUSIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Educational and Media Intervention for medulloblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Eflornithine for medulloblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elraglusib for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELRAGLUSIB + Gemcitabine Hydrochloride for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELRAGLUSIB + NAB-PACLITAXEL + Gemcitabine Hydrochloride for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ERAS-601 for chordomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + PEMBROLIZUMAB + Temozolomide for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + PEMBROLIZUMAB + Temozolomide for gliosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + Therapeutic Conventional Surgery + PEMBROLIZUMAB + Temozolomide for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + Therapeutic Conventional Surgery + PEMBROLIZUMAB + Temozolomide for gliosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fluzoparib with Temozolomide for glioblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Hypofractionated re-irradiation + MANNITOL + Cetuximab for glioblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
IA Carboplatin + IA Caelyx for glioblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
IA Carboplatin + IA Etoposide Phosphate for glioblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
IBI310 + SINTILIMAB + SURUFATINIB for neuroendocrine tumorsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
IDH1 peptide vaccine for gliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
IDH1-vac for glioblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
IDH1R132H peptide vaccine for gliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
IDH1R132H peptide vaccine + AVELUMAB for gliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Idroxioleate Sodium for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ipatasertib + atezolizumab for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan + ELRAGLUSIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Irradiation + Surgical resection + PEGFILGRASTIM + Vincristine + ETOPOSIDE + TOPOTECAN + Cyclophosphamide + Carboplatin + FILGRASTIM + CISPLATIN + Methotrexate for medulloblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ivoximab 20 mg/kg, ivgtt, Q4W + Temozolomide for gliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
JBI-778 for glioblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
JK-1201I + Temozolomide for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + SARGRAMOSTIM + SVN53-67/M57-KLH PEPTIDE VACCINE + INCOMPLETE FREUND'S ADJUVANT + Temozolomide for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + SARGRAMOSTIM + SVN53-67/M57-KLH PEPTIDE VACCINE + INCOMPLETE FREUND'S ADJUVANT + Temozolomide for gliosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
LCB84 for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lenvatinib for glioblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Lomustine + ELRAGLUSIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Low-dose Radiotherapy + SINTILIMAB for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lurbinectedin for neuroendocrine tumorsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
LUTETIUM OXODOTREOTIDE LU-177 for neuroendocrine tumorsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
M032 + PEMBROLIZUMAB for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
M032 + PEMBROLIZUMAB for gliosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + AFATINIB + AFATINIB DIMALEATE for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Sunitinib Malate for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Vismodegib for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ERDAFITINIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + LAROTRECTINIB + LAROTRECTINIB SULFATE for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Bone Marrow Aspiration + Bone Marrow Biopsy + Clinical Observation + Computed Tomography + Ultrasound + ETOPOSIDE + Doxorubicin hydrochloride + Cyclophosphamide + Carboplatin for ganglioneuroblastomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Computed Tomography + Cytology Specimen Collection Procedure + COPANLISIB HYDROCHLORIDE + COPANLISIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for chordomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for pheochromocytomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for seminomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for chordomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for pheochromocytomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for seminomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Lumbar Puncture + Radiation Therapy + Dabrafenib Mesylate + TRAMETINIB DIMETHYL SULFOXIDE for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Clinical Observation + Computed Tomography + Ultrasound for ganglioneuroblastomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Laboratory Biomarker Analysis + Radiation Therapy + Vincristine + Lomustine + Cyclophosphamide + CISPLATIN + Vincristine Sulfate for medulloblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Maximal surgical resection + Radical radiotherapy + Stupp regimen (oral temozolomide) + THIOTEPA for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mesna + Paclitaxel + Ifosfamide for neoplasms, germ cell and embryonalTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Metformin hydrochloride for medulloblastomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Niraparib for glioblastomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ommaya/VPS + Surgical resection + PEGFILGRASTIM + Vincristine + TOPOTECAN + Cyclophosphamide + Carboplatin + FILGRASTIM + CISPLATIN + Methotrexate for medulloblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Onfekafusp alfa for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Optune System + PEMBROLIZUMAB + Temozolomide for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Palacaparib for astrocytomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Palacaparib + Datopotamab Deruxtecan for astrocytomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Palacaparib + Temozolomide for astrocytomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pembrolizumab + lenvatinib for neuroendocrine tumorsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Perillyl alcohol for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phentermine / Topiramate Extended Release Oral Capsule [Qsymia] for craniopharyngiomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo (for Syntocinon) + Oxytocin for craniopharyngiomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Placebo + Metformin for medulloblastomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Radiodynamic therapy + AMINOLEVULINIC ACID HYDROCHLORIDE for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sacituzumab govitecan for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Sbrt for neuroendocrine tumorsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Selinexor for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Selpercatinib for carcinoma, medullaryPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Sonication for opening of blood-brain barrier + Carboplatin + NAB-PACLITAXEL for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonication for opening of blood-brain barrier + Carboplatin + NAB-PACLITAXEL for gliosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Srs + retifanlimab + ragifilimab for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Subventricular Zone radiation for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Surgical resection + PEGFILGRASTIM + Vincristine + TOPOTECAN + Cyclophosphamide + Carboplatin + FILGRASTIM + CISPLATIN + Methotrexate for medulloblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Surufatinib Combined With Temozolomide and S-1 for neuroendocrine tumorsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tarlatamab for carcinoma, neuroendocrinePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Tarlatamab + Temozolomide for gliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Temozolomide for glioblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Temozolomide for neuroendocrine tumorsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tovecimig for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Trametinib + DABRAFENIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Trametinib and Nivolumab for gliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
transarterial radioembolization + CAPECITABINE + Temozolomide for neuroendocrine tumorsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
TRASTUZUMAB DERUXTECAN + Palacaparib for astrocytomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vebreltinib for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.